Arterial CO2 as a Potent Coronary Vasodilator: A Preclinical PET/MR Validation Study with Implications for Cardiac Stress Testing

Hsin‐Jung Yang, Damini Dey, Jane Sykes, Michael A. Klein, John Butler, Michael S. Kovacs, Olivia Sobczyk, Behzad Sharif, Xiaoming Bi, Avinash Kali, Ivan Cokic, Richard Tang, Roya Yumul, Antonio Hernandez Conte, Sotirios A. Tsaftaris, Mourad Tighiouart, Debiao Li, Piotr J. Slomka, Daniel S. Berman, Frank S. Prato, Joseph A. Fisher, Rohan DharmakumarJournal of Nuclear Medicine 2017 · DOI

Abstract

Myocardial blood flow (MBF) is the critical determinant of cardiac function. However, its response to increases in partial pressure of arterial CO2 (PaCO2), particularly with respect to adenosine, is not well characterized because of challenges in blood gas control and limited availability of validated approaches to ascertain MBF in vivo. Methods: By prospectively and independently controlling PaCO2 and combining it with 13N-ammonia PET measurements, we investigated whether a physiologically tolerable hypercapnic stimulus (~25 mm Hg increase in PaCO2) can increase MBF to that observed with adenosine in 3 groups of canines: without coronary stenosis, subjected to non-flow-limiting coronary stenosis, and after preadministration of caffeine. The extent of effect on MBF due to hypercapnia was compared with adenosine. Results: In the absence of stenosis, mean MBF under hypercapnia was 2.1 ± 0.9 mL/min/g and adenosine was 2.2 ± 1.1 mL/min/g; these were significantly higher than at rest (0.9 ± 0.5 mL/min/g, P < 0.05) and were not different from each other (P = 0.30). Under left-anterior descending coronary stenosis, MBF increased in response to hypercapnia and adenosine (P < 0.05, all territories), but the effect was significantly lower than in the left-anterior descending coronary territory (with hypercapnia and adenosine; both P < 0.05). Mean perfusion defect volumes measured with adenosine and hypercapnia were significantly correlated (R = 0.85) and were not different (P = 0.12). After preadministration of caffeine, a known inhibitor of adenosine, resting MBF decreased; and hypercapnia increased MBF but not adenosine (P < 0.05). Conclusion: Arterial blood CO2 tension when increased by 25 mm Hg can induce MBF to the same level as a standard dose of adenosine. Prospectively targeted arterial CO2 has the capability to evolve as an alternative to current pharmacologic vasodilators used for cardiac stress testing.

Introduction

To diagnose coronary artery disease, clinicians perform stress tests to evaluate myocardial perfusion under demand. For patients unable to exercise, pharmacological vasodilators like adenosine are used to mimic exercise-induced hyperemia. However, these drugs present several clinical challenges: they can cause significant side effects (chest pain, hypotension), their effects are neutralized by caffeine consumption, and they have relatively slow reversibility.

While the vasodilatory properties of CO2 have been known for decades, the lack of precise control over blood gas levels has prevented its clinical application. This study utilizes a novel gas-control system to investigate whether precisely controlled hypercapnia can serve as a potent, "caffeine-proof" alternative to traditional pharmacological stressors.

Methods

The researchers employed a preclinical canine model using a PET/MR imaging suite. The core of the methodology was the RespirAct system, a computerized gas blender that enables independent and rapid control of end-tidal CO2 ($P_{ET}CO_2$) and Oxygen ($P_{ET}O_2$).

Myocardial Blood Flow (MBF) was quantified using $^{13}$N-ammonia PET across three experimental groups: intact hearts ($n=10$), hearts with LAD artery stenosis ($n=7$), and hearts pre-treated with caffeine ($n=5$). Hypercapnia was defined as a ~25 mm Hg increase in arterial CO2 above baseline, maintained under isoxic conditions. Results were directly compared against a standard clinical dose of adenosine (140 $\mu$g/kg/min).

Key Results

Physiological Equivalence of CO2 and Adenosine

In healthy hearts, global MBF rose from a resting baseline of ~0.9 mL/min/g to ~2.1 mL/min/g under hypercapnia and ~2.2 mL/min/g with adenosine. Statistical analysis confirmed that the hyperemic response to a 25 mm Hg increase in CO2 is indistinguishable from a full clinical dose of adenosine ($P=0.30$). Furthermore, the Myocardial Perfusion Reserve (MPR) was comparable between both stressors.

Global MBF and MPR comparisons across rest, CO2, and adenosine stressors.

Detection of Perfusion Defects

In the stenosis group, both CO2 and adenosine successfully identified reduced flow in the affected LAD territory. The study found a high correlation ($R=0.85$) between the total perfusion defect (TRP) volumes measured by both methods. Visual scoring by blinded observers yielded 89% sensitivity and 98% specificity for CO2-based imaging when compared to the adenosine gold standard.

Validation of CO2-induced perfusion defect detection compared to adenosine.

The Caffeine Challenge

A critical finding of this study is the "caffeine-proof" nature of the CO2 stimulus. Caffeine is a potent inhibitor of the A2A receptors that adenosine requires to induce vasodilation. Following caffeine administration, adenosine failed to significantly increase MBF ($P > 0.05$). In contrast, hypercapnia continued to induce significant hyperemia ($P < 0.05$), demonstrating that CO2-induced vasodilation bypasses the adenosine receptor pathway.

Discussion and Conclusion

This study demonstrates that precisely controlled arterial CO2 is a potent coronary vasodilator capable of matching the diagnostic performance of adenosine. The rapid onset and offset of the CO2 stimulus (reversible within 2–3 breaths) suggests a superior safety profile compared to long-acting pharmacological agents.

While further human clinical trials are necessary to account for species-specific CO2 sensitivity and patient comfort (addressing the "air hunger" sensation associated with hypercapnia), these results suggest that breath-based stress testing could provide a "green," cost-effective, and caffeine-resistant alternative to current clinical standards.

Summary updated

Abstract

Myocardial blood flow (MBF) is the critical determinant of cardiac function. However, its response to increases in partial pressure of arterial CO<sub>2</sub> (PaCO<sub>2</sub>), particularly with respect to adenosine, is not well characterized because of challenges in blood gas control and limited availability of validated approaches to ascertain MBF in vivo. <b>Methods:</b> By prospectively and independently controlling PaCO<sub>2</sub> and combining it with <sup>13</sup>N-ammonia PET measurements, we investigated whether a physiologically tolerable hypercapnic stimulus (∼25 mm Hg increase in PaCO<sub>2</sub>) can increase MBF to that observed with adenosine in 3 groups of canines: without coronary stenosis, subjected to non-flow-limiting coronary stenosis, and after preadministration of caffeine. The extent of effect on MBF due to hypercapnia was compared with adenosine. <b>Results:</b> In the absence of stenosis, mean MBF under hypercapnia was 2.1 ± 0.9 mL/min/g and adenosine was 2.2 ± 1.1 mL/min/g; these were significantly higher than at rest (0.9 ± 0.5 mL/min/g, <i>P</i> < 0.05) and were not different from each other (<i>P</i> = 0.30). Under left-anterior descending coronary stenosis, MBF increased in response to hypercapnia and adenosine (<i>P</i> < 0.05, all territories), but the effect was significantly lower than in the left-anterior descending coronary territory (with hypercapnia and adenosine; both <i>P</i> < 0.05). Mean perfusion defect volumes measured with adenosine and hypercapnia were significantly correlated (<i>R</i> = 0.85) and were not different (<i>P</i> = 0.12). After preadministration of caffeine, a known inhibitor of adenosine, resting MBF decreased; and hypercapnia increased MBF but not adenosine (<i>P</i> < 0.05). <b>Conclusion:</b> Arterial blood CO<sub>2</sub> tension when increased by 25 mm Hg can induce MBF to the same level as a standard dose of adenosine. Prospectively targeted arterial CO<sub>2</sub> has the capability to evolve as an alternative to current pharmacologic vasodilators used for cardiac stress testing.
BibTeX
@article{yang2017arterial,
  author = {Hsin‐Jung Yang and Damini Dey and Jane Sykes and Michael A. Klein and John Butler and Michael S. Kovacs and Olivia Sobczyk and Behzad Sharif and Xiaoming Bi and Avinash Kali and Ivan Cokic and Richard Tang and Roya Yumul and Antonio Hernandez Conte and Sotirios A. Tsaftaris and Mourad Tighiouart and Debiao Li and Piotr J. Slomka and Daniel S. Berman and Frank S. Prato and Joseph A. Fisher and Rohan Dharmakumar},
  title = {{Arterial CO<sub>2</sub> as a Potent Coronary Vasodilator: A Preclinical PET/MR Validation Study with Implications for Cardiac Stress Testing}},
  journal = {Journal of Nuclear Medicine},
  year = {2017},
  doi = {10.2967/jnumed.116.185991},
}
Figure